Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
April 13, 2026
in Health and Longevity
Reading Time: 3 mins read
A A
0
AI Investment Boom: How Tech Giants Are Leading the Charge

"Machine Learning & Artificial Intelligence" by mikemacmarketing is licensed under CC BY 2.0

Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp
  • AI scribe adoption was associated with 13 fewer minutes per day in the EHR and 16 fewer minutes on documentation — a 3% and 10% reduction respectively — according to a JAMA study covering more than 8,500 clinicians across five academic medical centers
  • Primary care providers saw the biggest gains: 25 fewer minutes in the EHR and nearly 27 fewer minutes on clinical notes daily; clinicians who used scribes in 50%+ of visits saved 21 fewer EHR minutes and 27 fewer documentation minutes
  • AI scribe adoption was linked to 0.5 additional patient visits per week and $167/month in additional evaluation and management revenue per clinician — described by researchers as a “conservative lower bound” of financial benefit that health systems can compare against implementation costs
  • The tools did not reduce after-hours EHR work, suggesting clinicians are using reclaimed time for other tasks like responding to patient messages or reviewing AI-generated notes for accuracy — a finding that limits the burnout-reduction case for scribes

What Happened?

A major new study published in JAMA provides the most rigorous large-scale evidence to date on how AI scribes affect clinical workflows. Conducted across five academic medical centers with more than 8,500 clinicians, the research found that adopting an AI scribe — which records provider-patient conversations and generates draft clinical notes — was associated with 13 fewer minutes per day in the electronic health record and 16 fewer minutes on documentation. The tools also increased weekly visit volume by 0.5 appointments per clinician, translating to $167 in additional monthly revenue. Primary care providers, female clinicians, advanced practice providers, and those who used scribes most frequently saw the largest time savings — with some primary care physicians reclaiming nearly 27 minutes daily from documentation alone.

Why It Matters?

Administrative burden — particularly time spent on EHR documentation — has become one of the leading drivers of clinician burnout, a crisis that has worsened physician shortages and contributed to rising healthcare costs. AI scribes from companies including Microsoft (Nuance), Oracle, Epic, Amazon, and Abridge have been adopted rapidly by health systems on the promise of reducing that burden, but rigorous evidence on their actual impact has been scarce. This JAMA study fills a critical gap. The 10% reduction in documentation time and 1.7% increase in visit volume suggest meaningful, if modest, productivity gains — and the $167/month revenue bump, while small, gives health systems a starting point for calculating ROI against implementation costs. The finding that after-hours EHR work did not decline complicates the burnout narrative, however, suggesting clinicians may be absorbing time savings into other administrative tasks rather than logging off earlier.

What’s Next?

The AI scribe market is expanding rapidly, with major health IT vendors racing to embed ambient documentation into existing EHR workflows. The JAMA study’s subgroup findings — that higher-frequency users and primary care clinicians benefit most — suggest that health system ROI on scribe deployment will depend heavily on implementation depth and specialty mix. Researchers note that the $167/month revenue figure is a conservative floor estimate; full financial modeling would need to account for reduced overtime, lower turnover, and patient throughput gains. Future research will need to address whether time savings compound over time as clinicians become more fluent with AI-generated notes, and whether the absence of after-hours relief eventually closes as note quality improves and review time falls.

Source: Healthcare Dive

Previous Post

Iran Still Has Thousands of Missiles — and Intelligence Says It Can Get More Out of the Ground

Next Post

Oil Could Hit $140–$150 If the Hormuz Blockade Holds, Veteran Trader Warns — and $103 Is Just the Beginning

Recommended For You

385 Million Patient Records Breached and Counting — DentaQuest’s 15M-Person Hack Leads a New Wave of Healthcare Cybersecurity Disasters

by Team Lumida
3 days ago
person sitting while using laptop computer and green stethoscope near

The updated Healthcare Dive breach tracker reveals a sector in crisis: DentaQuest's 15M breach in 2026, Conduent's 62M in 2025, and Change Healthcare's record 192.7M in 2024.

Read more

Healthcare Stocks Are Now an Implicit AI Short — Semiconductors and Pharma Have Flipped to Negative Correlation

by Team Lumida
4 days ago
turned on monitoring screen

A structural shift is underway in equity markets: the VanEck Semiconductor ETF and the State Street Health Care ETF have moved into negative correlation, meaning healthcare has effectively...

Read more

Patients Are Using AI to Interpret Their Medical Test Results Before Seeing Doctors — And Doctors Are Struggling to Untangle the Errors

by Team Lumida
1 week ago
doctor holding red stethoscope

Roughly a third of American adults now consult AI for health advice, and the majority view test results online before speaking with a doctor — a trend accelerated...

Read more

Novo Nordisk’s $10 Billion Cardiovascular Bet Fails — Ziltivekimab Misses Heart Attack and Stroke Endpoint, Stock Drops 10.5%

by Team Lumida
2 weeks ago
Novo Nordisk Q2 2024 Earnings Highlights

Novo Nordisk's experimental drug ziltivekimab — a monthly IL-6 inhibitor injection targeting cardiovascular disease, chronic kidney disease, and inflammation in a market Jefferies estimates at $10B+ annually —...

Read more

Trump Administration to End $3.6 Billion Medicare Drug Premium Subsidy — Seniors Face Higher Part D Costs in 2027

by Team Lumida
2 weeks ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The Trump administration will not renew the Part D Low Income Premium Subsidy program after 2026, eliminating $3.6 billion in annual payments to insurers that have been holding...

Read more

80% of People Are Deficient in Essential Vitamins — Here Are the 10 You Actually Need and Where to Get Them

by Team Lumida
3 weeks ago
oranges, peas, and limes on a wooden table

Most people are not getting enough of the 13 essential vitamins their bodies require — here is a practical guide to the most critical nutrients, what they do,...

Read more

Whoop Enters Clinical Care With Joint Replacement Recovery Pilot — Can Wearable Biometrics Reduce Opioids and Speed Recovery?

by Team Lumida
4 weeks ago
a close up of a human skull on a black background

Whoop and surgical software company Kinomatic have launched a 12-week pilot program called Restore across three California orthopedic clinics to test whether continuous biometric monitoring — heart rate...

Read more

$399 Signal Ring Claims to Replace the Blood Pressure Cuff — No Calibration, No Subscription, Clinical Trial at Stanford

by Team Lumida
1 month ago
Fingers hold a black smart ring with circuits visible.

Vital Signals, a three-year-old startup, has launched a $399 Signal Ring that claims to track blood pressure as accurately as a traditional arm cuff — without requiring any...

Read more

Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

by Team Lumida
1 month ago
Novo’s Obesity Pill Commands 89% Market Share — Lilly’s Foundayo Captures Just 11% After Three Months on Market

Novo Nordisk's Wegovy pill has seized 89% of new oral obesity pill prescriptions since its January 2026 launch, leaving Eli Lilly's Foundayo — launched in April — with...

Read more

Information Blocking in Healthcare Is Down — But a Stubborn Minority of IT Vendors Keep Doing It Routinely

by Team Lumida
1 month ago
doctor holding red stethoscope

The share of health information exchanges reporting instances of information blocking fell from over 90% in 2019 to 71% in 2025, according to new ONC data — but...

Read more
Next Post
Geopolitical Forces Shape Oil Market Dynamics

Oil Could Hit $140–$150 If the Hormuz Blockade Holds, Veteran Trader Warns — and $103 Is Just the Beginning

Bitcoin Could Drop to $50K Before a Potential Fed-Driven Rally

The Bitcoin Leverage Stack Just Got a New Layer: Stablecoins Backed by Strategy's Preferred Shares

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

black flat screen tv turned on displaying 11

Netflix Binge-Watching Linked to Shorter Lifespan: Here’s How to Mitigate the Risk

June 17, 2024
China’s AI Startups Challenge Global Leaders Amid U.S. Trade Curbs

The AI Cold War That Will Redefine Everything

November 11, 2025
US CPI Falls for First Time Since 2020 — Gasoline Prices Plunge 10%, But Iran War Risks Keep Fed on Edge

US CPI Falls for First Time Since 2020 — Gasoline Prices Plunge 10%, But Iran War Risks Keep Fed on Edge

July 15, 2026

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto data centers Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Intel Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018